Castle Biosciences, Inc.
HealthcareNASDAQ:CSTL · NASDAQ Global Market
-$0.31 today
Vol 0.15M · Avg 0.38M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$339.9M of revenue converted into -$12.8M of net income for the selected period. Gross margin is 77.0% and net margin is -3.8%, showing how much revenue survives after costs and taxes. EPS is $-0.44, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $344.2M +3.7% | $332.1M +51.1% | $219.8M +60.4% | $137.0M +45.7% | $94.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $71.0M +18.0% | $60.2M +33.8% | $45.0M +40.5% | $32.0M +102.3% | $15.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $273.2M +0.5% | $271.9M +55.5% | $174.8M +66.4% | $105.0M +34.2% | $78.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 79.4% -2.5pp | 81.9% +2.3pp | 79.5% +2.9pp | 76.6% -6.5pp | 83.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $51.9M -0.4% | $52.0M -2.9% | $53.6M +19.4% | $44.9M +51.5% | $29.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $229.3M +14.6% | $200.0M +11.0% | $180.2M +26.0% | $143.0M +64.9% | $86.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $316.0M +20.1% | $263.2M +8.4% | $242.8M +36.5% | $177.9M +50.3% | $118.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $40.8M +154.9% | $16.0M +29.7% | $12.3M +16.9% | $10.5M +209.5% | $3.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $11.3M -70.3% | $38.1M +184.7% | -$45.0M +22.8% | -$58.3M -59.4% | -$36.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 3.3% -8.2pp | 11.5% +32.0pp | -20.5% +22.1pp | -42.6% -3.7pp | -38.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$42.8M -593.8% | $8.7M +112.8% | -$68.0M +6.7% | -$72.9M -81.8% | -$40.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -12.4% -15.0pp | 2.6% +33.5pp | -30.9% +22.2pp | -53.2% -10.6pp | -42.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.8M -8.9% | $12.9M +21.6% | $10.6M +167.7% | $4.0M +5735.3% | $68.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $86.0K -85.1% | $577.0K +5145.5% | $11.0K -35.3% | $17.0K +1600.0% | $1.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $13.3M +3.1% | $12.9M +21.5% | $10.6M +168.6% | $4.0M +5797.0% | $67.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$29.5M -236.9% | $21.6M +137.6% | -$57.4M +16.7% | -$68.9M -72.2% | -$40.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -8.6% -15.1pp | 6.5% +32.6pp | -26.1% +24.2pp | -50.3% -7.8pp | -42.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$5.4M -261.4% | $3.3M +3186.1% | $101.0K +105.7% | -$1.8M +79.7% | -$8.7M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$24.2M -232.4% | $18.2M +131.7% | -$57.5M +14.4% | -$67.1M -114.6% | -$31.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -7.0% -12.5pp | 5.5% +31.6pp | -26.1% +22.8pp | -49.0% -15.7pp | -33.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -225.8% | $1 +130.8% | -$2 +17.1% | -$3 -108.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -233.9% | $1 +129.0% | -$2 +17.1% | -$3 -108.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $29.0M +4.4% | $27.8M +3.6% | $26.8M +2.9% | $26.1M +3.6% | $25.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $29.0M -0.9% | $29.3M +9.2% | $26.8M +2.9% | $26.1M +3.6% | $25.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
AMN Healthcare Services, Inc.
NYSE:AMN
$1.19B
CareDx, Inc
NASDAQ:CDNA
$1.19B
Personalis, Inc.
NASDAQ:PSNL
$851.63M
Geron Corporation
NASDAQ:GERN
$737.75M
Evolent Health, Inc.
NYSE:EVH
$539.91M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
Embecta Corp.
NASDAQ:EMBC
$183.92M
DarioHealth Corp.
NASDAQ:DRIO
$51.63M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CSTL generate?
Castle Biosciences, Inc. (CSTL) reported $344.23M of revenue in fiscal 2025.
Is CSTL profitable?
Castle Biosciences, Inc. (CSTL) reported -$24,158,000.00 of net income, with a net margin of -7.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.